The specific aims of this investigation are: (i) the modification of the DNA encoding fragment B at three restriction sites such that a cysteine codon is C-terminal and a unique Pstl site is introduced just upstream from the Cys codon; (ii) the assembly of hybrid toxins at the level of protein chemistry, using the sulfhydryl group of the C-terminal Cys to form disulfide linkage with modified thyrotropin releasing hormone and melanocyte stimulating hormone as the cell receptor-specific ligand; (iii) the assembly of hybrid toxin genes through fusion of a synthetic oligonucleotide encoding Alpha-MSH with varying amounts of the tox gene; (iv) expression and purification of the toxin related-hormone fusion polypeptides; and (v) the determination of specific toxicity and spectrum of cytotoxicity in both mouse and human cell lines. The long range objectives of this proposal are to construct a family of toxin-hormone hybrid genes and to test their respective protein fusion products for targeted cytotoxicity. The toxin-hormone hybrid genes will be assembled from those portions of the diphtheria toxin structural gene which include the enzymatically active fragment A and varying amounts of the DNA which encode the B fragment. Preliminary results have clearly shown that we have been able to genetically construct, express, and demonstrate selective cytotoxicity of one of the diphtheria toxin-related Alpha-MSH fusion proteins described in this application. The comparative cytotoxicities of the toxin-related Alpha-MSH hybrids that are assembled through both disulfide linkage and gene fusion should provide additional insight into those functional domains of diphtheria toxin fragment B which (i) are involved in the binding of diphtheria toxin to its receptor on the surface of sensitive eukaryotic cells, and (ii) are essential for the membrane translocation of fragment A. In addition, the genetic construction and expression of these gene fusions whose products have targeted cytotoxicity toward human melanoma cells raises the potential for the development of a new class of therapeutic biologicals for malignant melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041746-03
Application #
3182502
Study Section
Microbial Physiology and Genetics Subcommittee 2 (MBC)
Project Start
1986-03-01
Project End
1989-02-28
Budget Start
1988-03-01
Budget End
1989-02-28
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Boston University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02118
Jean, L F; Waters, C A; Keemy, D et al. (1993) Site-directed and deletion mutational analysis of the receptor binding domain of the interleukin-6 receptor targeted fusion toxin DAB389-IL-6. Protein Eng 6:305-11
Tatro, J B; Wen, Z; Entwistle, M L et al. (1992) Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res 52:2545-8
Strom, T B; Kelley, V R; Woodworth, T G et al. (1992) Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules. Immunol Rev 129:131-63
Kiyokawa, T; Williams, D P; Snider, C E et al. (1991) Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Ann N Y Acad Sci 636:331-9
Strom, T B; Anderson, P L; Rubin-Kelley, V E et al. (1991) Immunotoxins and cytokine toxin fusion proteins. Ann N Y Acad Sci 636:233-50
Landgraf, B E; Williams, D P; Murphy, J R et al. (1991) Conformational perturbation of interleukin-2: a strategy for the design of cytokine analogs. Proteins 9:207-16
Kiyokawa, T; Williams, D P; Snider, C E et al. (1991) Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 4:463-8
Lakkis, F; Steele, A; Pacheco-Silva, A et al. (1991) Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur J Immunol 21:2253-8
Jean, L F; Murphy, J R (1991) Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng 4:989-94
Wen, Z L; Tao, X; Lakkis, F et al. (1991) Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation. J Biol Chem 266:12289-93

Showing the most recent 10 out of 24 publications